4-(3-Pyridyl)-1,2,4-triazolodone-3,5-dione
|
- $210 - $2000
- Product name: 4-(3-Pyridyl)-1,2,4-triazolodone-3,5-dione
- CAS: 1076199-39-7
- MF: C7H6N4O2
- MW: 178.15
- EINECS:
- MDL Number:MFCD18382426
- Synonyms:4-(3-Pyridyl)-1,2,4-triazolodone-3,5-dione;4-(3-Pyridinyl)-;Pyridyl Urazol [4-(3-Pyridyl)-1,2,4-triazolidine-3,5-dione];Pyridyl Urazol;1,2,4-Triazolidine-3,5-dione, 4-(3-pyridinyl)-;4-pyridin-3-yl-1,2,4-triazolidine-3,5-dione
3 prices
Selected condition：
Brand
- Medical Isotopes, Inc.
- TRC
Package
- 100mg
- 0.5g
- ManufacturerMedical Isotopes, Inc.
- Product number13292
- Product description4-(3-Pyridyl)-1,2,4-triazolodone-3,5-dione
- Packaging100mg
- Price$875
- Updated2021-12-16
- Buy
- ManufacturerMedical Isotopes, Inc.
- Product number13292
- Product description4-(3-Pyridyl)-1,2,4-triazolodone-3,5-dione
- Packaging0.5g
- Price$2000
- Updated2021-12-16
- Buy
- ManufacturerTRC
- Product numberP996900
- Product description4-(3-Pyridyl)-1,2,4-triazolodone-3,5-dione
- Packaging100mg
- Price$210
- Updated2021-12-16
- Buy
| Manufacturer | Product number | Product description | Packaging | Price | Updated | Buy |
|---|---|---|---|---|---|---|
| Medical Isotopes, Inc. | 13292 | 4-(3-Pyridyl)-1,2,4-triazolodone-3,5-dione | 100mg | $875 | 2021-12-16 | Buy |
| Medical Isotopes, Inc. | 13292 | 4-(3-Pyridyl)-1,2,4-triazolodone-3,5-dione | 0.5g | $2000 | 2021-12-16 | Buy |
| TRC | P996900 | 4-(3-Pyridyl)-1,2,4-triazolodone-3,5-dione | 100mg | $210 | 2021-12-16 | Buy |
Properties
Melting point :>270°C (dec.)
Density :1.457±0.06 g/cm3(Predicted)
storage temp. :-20°C Freezer, Under Inert Atmosphere
solubility :DMSO (Slightly)
form :Solid
pka :5.20±0.30(Predicted)
color :Off-White to Pale Yellow
Density :1.457±0.06 g/cm3(Predicted)
storage temp. :-20°C Freezer, Under Inert Atmosphere
solubility :DMSO (Slightly)
form :Solid
pka :5.20±0.30(Predicted)
color :Off-White to Pale Yellow
Safety Information
| Symbol(GHS): | ||||||||
|---|---|---|---|---|---|---|---|---|
| Signal word: | ||||||||
| Hazard statements: |
|
|||||||
| Precautionary statements: |
|